How should tofacitinib be prescribed and monitored in adult patients with existing cardiovascular disease?

Tofacitinib Use in Patients with Cardiovascular Disease

Tofacitinib should be avoided in patients with existing cardiovascular disease, particularly those with a history of atherosclerotic cardiovascular disease (ASCVD), and should only be used if no suitable alternative exists. 1, 2

Key Evidence from ORAL Surveillance Trial

The FDA issued a Drug Safety Alert in February 2021 based on the ORAL Surveillance trial, which demonstrated increased cardiovascular risk in patients aged ≥50 years with at least one cardiovascular risk factor. 1 This landmark trial showed:

• MACE (myocardial infarction, stroke, cardiovascular death) risk was 33% higher with combined tofacitinib doses versus TNF inhibitors (HR 1.33,95% CI 0.91-1.94), failing to meet noninferiority criteria. 3
• Cancer risk was 48% higher with tofacitinib versus TNF inhibitors (HR 1.48,95% CI 1.04-2.09). 3

Risk Stratification by Cardiovascular History

Patients WITH History of ASCVD (Highest Risk)

In patients with established ASCVD, the cardiovascular risk is substantially elevated:

• MACE incidence was approximately double with tofacitinib (8.3% for 5 mg BID, 7.7% for 10 mg BID) versus TNF inhibitors (4.2%). 2
• The hazard ratio for combined tofacitinib doses versus TNF inhibitors was 1.98 (95% CI 0.95-4.14) in this subgroup. 2
• These patients should preferentially receive TNF inhibitors or other biologics rather than tofacitinib. 2

Patients WITHOUT History of ASCVD (But With CV Risk Factors)

Even in patients without established ASCVD but with prevalent cardiovascular risk factors:

• MACE risk with tofacitinib 5 mg BID appeared similar to TNF inhibitors (HR 1.03,95% CI 0.62-1.73). 2
• However, the 10 mg BID dose showed a trend toward increased risk (HR 1.25,95% CI 0.76-2.07). 2
• Any absolute risk excess is likely low, but cannot be definitively excluded due to limited statistical power. 2

Dose-Specific Considerations

The 10 mg BID Dose Carries Additional Risks

• Venous thromboembolism (VTE) risk is dose-dependent, with higher rates at 10 mg BID versus 5 mg BID or TNF inhibitors. 4, 5
• The composite endpoint of MACE-8 plus VTE showed similar risk with 5 mg BID versus TNF inhibitors (HR 1.12,95% CI 0.82-1.52), but significantly higher risk with 10 mg BID (HR 1.38,95% CI 1.02-1.85). 5
• The 10 mg BID dose should be avoided in patients with any cardiovascular risk factors. 5

Specific Cardiovascular Risk Factors to Assess

Before initiating tofacitinib, evaluate these critical risk factors that predict MACE:

• Age ≥65 years (increased risk across all extended MACE definitions). 5, 6
• Hypertension (remained significantly associated with MACE in multivariable analysis). 6
• Total cholesterol to HDL cholesterol ratio (higher ratios predict increased MACE). 6
• Prior VTE history (strong predictor of recurrent VTE). 4
• BMI ≥35 kg/m² (independent VTE risk factor). 4
• History of chronic lung disease (associated with VTE risk). 4

Monitoring Requirements During Treatment

Lipid Monitoring

• Check lipid panel at baseline and after 24 weeks of treatment. 6
• Increases in HDL cholesterol after 24 weeks were associated with decreased future MACE risk. 6
• Paradoxically, increases in total cholesterol and LDL cholesterol were not associated with increased MACE risk. 6
• Elevated ESR trends with increased future MACE risk and should be monitored. 6

Cardiovascular Surveillance

• Monitor for signs/symptoms of myocardial infarction (highest individual component risk with tofacitinib). 5
• Assess for VTE symptoms regularly, particularly in the first 6 months and in patients with risk factors. 4
• VTE incidence rates remain consistent across 6-month intervals, indicating persistent rather than early-only risk. 4

Alternative Treatment Recommendations

For Patients with Cardiovascular Disease

According to the 2021 ACR guidelines:

• TNF inhibitors remain the preferred biologic option in patients with cardiovascular risk factors. 1
• The European Medicines Agency specifically states tofacitinib should only be used in elderly patients (≥65 years) with cardiovascular risk factors if no alternative exists. 7

For Patients with Active Disease Despite csDMARDs

• Consider TNF inhibitors, abatacept, or rituximab as first-line biologics over JAK inhibitors in patients with cardiovascular disease. 1
• If tofacitinib must be used, limit to 5 mg BID dose and ensure intensive cardiovascular monitoring. 2, 5

Drug Interactions Affecting Cardiovascular Risk

Tofacitinib metabolism is primarily via CYP3A4 (70% hepatic, 30% renal excretion):

• Strong CYP3A4 inhibitors (ketoconazole) require dose reduction to avoid increased drug exposure. 7, 8
• CYP3A4 inducers (rifampicin) may require dose increase, though this should be avoided in cardiovascular disease patients given the need to minimize exposure. 7
• Statin use was associated with MACE risk in baseline analyses, likely reflecting underlying cardiovascular disease burden rather than drug interaction. 6

Contraindications in Cardiovascular Context

While not absolute contraindications, these situations warrant extreme caution or avoidance:

• History of ASCVD (myocardial infarction, stroke, peripheral vascular disease). 2
• Age ≥65 years with any additional cardiovascular risk factor. 7, 5
• Prior VTE or pulmonary embolism. 4
• Multiple cardiovascular risk factors (hypertension, diabetes, hyperlipidemia, smoking). 6, 3